On the stock market since 2022, it operates in the world of health and science. It has 24,561 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The gap is $7.3B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 17% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 15% — still a thick cushion, though costs have been eating into it lately.
It pays out $0.10 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 1% a year on average. At this size, speeding back up is not easy.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, HLNCF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HLNCF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.